BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37580710)

  • 1. CRISPR-Cas9 identifies growth-related subtypes of glioblastoma with therapeutical significance through cell line knockdown.
    Zhao N; Weng S; Liu Z; Xu H; Ren Y; Guo C; Liu L; Zhang Z; Ji Y; Han X
    BMC Cancer; 2023 Aug; 23(1):749. PubMed ID: 37580710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
    Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
    Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
    J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and prognostic significance of TCTN1 in human glioblastoma.
    Meng D; Chen Y; Zhao Y; Wang J; Yun D; Yang S; Chen J; Chen H; Lu D
    J Transl Med; 2014 Oct; 12():288. PubMed ID: 25304031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
    Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
    Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma.
    Nakazawa T; Morimoto T; Maeoka R; Matsuda R; Nakamura M; Nishimura F; Ouji N; Yamada S; Nakagawa I; Park YS; Ito T; Nakase H; Tsujimura T
    J Exp Clin Cancer Res; 2023 Aug; 42(1):205. PubMed ID: 37563692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
    Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establish six-gene prognostic model for glioblastoma based on multi-omics data of TCGA database.
    Lei CG; Jia XY; Sun WJ
    Yi Chuan; 2021 Jul; 43(7):665-679. PubMed ID: 34284982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioblastoma Multiforme: Fewer Tumor Copy Number Segments of the
    Lehrer S; Rheinstein PH; Rosenzweig KE
    Cancer Genomics Proteomics; 2018; 15(4):273-278. PubMed ID: 29976632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGF/EGFR upregulates and cooperates with Netrin-4 to protect glioblastoma cells from DNA damage-induced senescence.
    Li L; Huang Y; Gao Y; Shi T; Xu Y; Li H; Hyytiäinen M; Keski-Oja J; Jiang Q; Hu Y; Du Z
    BMC Cancer; 2018 Dec; 18(1):1215. PubMed ID: 30514230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translational validation of personalized treatment strategy based on genetic characteristics of glioblastoma.
    Oh YT; Cho HJ; Kim J; Lee JH; Rho K; Seo YJ; Choi YS; Jung HJ; Song HS; Kong DS; Seol HJ; Lee JI; Yoon Y; Kim S; Nam DH; Joo KM
    PLoS One; 2014; 9(8):e103327. PubMed ID: 25084005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Immune-Related lncRNA Prognostic Signature and Molecular Subtypes for Glioblastoma.
    Yu W; Ma Y; Hou W; Wang F; Cheng W; Qiu F; Wu P; Zhang G
    Front Immunol; 2021; 12():706936. PubMed ID: 34899682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glioblastoma Exhibits Inter-Individual Heterogeneity of TSPO and LAT1 Expression in Neoplastic and Parenchymal Cells.
    Cai L; Kirchleitner SV; Zhao D; Li M; Tonn JC; Glass R; Kälin RE
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA sequencing and Immunohistochemistry Reveal
    Esteve-Codina A; Alameda F; Carrato C; Pineda E; Arpí O; Martinez-García M; Mallo M; Gut M; Dabad M; Tortosa A; Del Barco S; Capellades J; Puig J; Gallego O; Pujol T; Oleaga L; Gil-Gil M; de Quintana-Schmidt C; Valduvieco I; Martinez-Cardús A; Bellosillo B; Muñoz-Marmol AM; Esteve A; Domenech M; Camins A; Craven-Bartle J; Villa S; Marruecos J; Domenech S; de la Iglesia N; Balana C
    Clin Cancer Res; 2021 Jan; 27(2):645-655. PubMed ID: 33106291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNAs involved in the EGFR pathway in glioblastoma.
    Xu B; Mei J; Ji W; Huo Z; Bian Z; Jiao J; Li X; Sun J; Shao J
    Biomed Pharmacother; 2021 Feb; 134():111115. PubMed ID: 33341046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High expression of RFX4 is associated with tumor progression and poor prognosis in patients with glioblastoma.
    Jeong HY; Kim HJ; Kim CE; Lee S; Choi MC; Kim SH
    Int J Neurosci; 2021 Jan; 131(1):7-14. PubMed ID: 32075484
    [No Abstract]   [Full Text] [Related]  

  • 18. ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.
    Dréan A; Rosenberg S; Lejeune FX; Goli L; Nadaradjane AA; Guehennec J; Schmitt C; Verreault M; Bielle F; Mokhtari K; Sanson M; Carpentier A; Delattre JY; Idbaih A
    J Neurooncol; 2018 Jul; 138(3):479-486. PubMed ID: 29520610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution differences in prognostic copy number alteration profiles in IDH-wild-type glioblastoma cause survival discrepancies across cohorts.
    Umehara T; Arita H; Yoshioka E; Shofuda T; Kanematsu D; Kinoshita M; Kodama Y; Mano M; Kagawa N; Fujimoto Y; Okita Y; Nonaka M; Nakajo K; Uda T; Tsuyuguchi N; Fukai J; Fujita K; Sakamoto D; Mori K; Kishima H; Kanemura Y
    Acta Neuropathol Commun; 2019 Jun; 7(1):99. PubMed ID: 31215469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZWINT: A potential therapeutic biomarker in patients with glioblastoma correlates with cell proliferation and invasion.
    Yang L; Han N; Zhang X; Zhou Y; Chen R; Zhang M
    Oncol Rep; 2020 Jun; 43(6):1831-1844. PubMed ID: 32323832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.